leadf
logo-loader
viewDirecta Plus PLC

Directa Plus lands contract to use graphene-based tech to treat hydrocarbon sludge

"Our commercialisation strategy for the key environmental sector is based on providing international oil and gas customers with a complete environmental solution and service based on our patented Grafysorber technology,” said Giulio Cesareo.

oil and gas operations
The contract is worth €150,000

Graphene specialist Directa Plus PLC (LON:DCTA) told investors it has landed a contract to treat and recover crude oil from producing wells onshore Europe.

The supply and services contract envisages the use of the company’s Grafysorber technology in the treatment of several thousand cubic meters of sludges and by-products. It has been valued at €150,000.

Directa Plus said it will provide a full service to the customer, an international oil and gas company, via a mobile treatment unit and it will operate the recovery process.

READ: Directa Plus pioneers graphene use as sector evolves

It is expected that the application of the Grafysorber technology will both improve the production process and potentially reduce costs.

"Our commercialisation strategy for the key environmental sector is based on providing international oil and gas customers with a complete environmental solution and service based on our patented Grafysorber technology,” said Giulio Cesareo, Directa Plus chief executive.

"I am pleased that we can today announce the first of what we hope will be a growing number of supply and service contracts with oil and gas producers as we seek to expand this business regionally and then globally."

The proprietary Grafysorber technology is described as a commercially-available graphene-based solution for treating water contaminated by hydrocarbons.

Directa Plus highlighted that it is at least five times more effective than current technologies, adsorbing more than 100 times its own weight of oil-based pollutants. It is sustainably produced, non-flammable and reusable.

Quick facts: Directa Plus PLC

Price: 81.99 GBX

AIM:DCTA
Market: AIM
Market Cap: £50.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Directa Plus PLC named herein, including the promotion by the Company of Directa Plus PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE jumps on AstraZeneca COVID-19 vaccine trial and easing...

FTSE 100 rallied in early trading on AstraZeneca’s COVID-19 vaccine trial and the easing of lockdown restrictions from December. London’s blue-chip index rose 20 to 6,371. AstraZeneca PLC (LON:AZN) announced that the coronavirus (COVID-19) vaccine it has developed with Oxford University was...

1 week, 3 days ago

2 min read